Epilepsy is one of the most frequent neurological disorders after stroke and headache, affecting over 70 million people worldwide, and it is now widely accepted that having epilepsy does not…
Content Section:
Articles
…such as loud snoring, witnessed apnoeas, nocturia, or a dry mouth, sore throat or headache on waking, or symptoms of restless legs syndrome such as nocturnal urge to move and…
Content Section:
Articles
…headache for up to 20% and increased anxiety with palpitations for some. Furthermore, the long 12-15 hour half-life undoubtedly increases the likelihood of insomnia [2]. Modafinil can decrease efficacy of…
Content Section:
Articles
…M.D., board-certified Neurologist and Medical Director and Chief Medical Officer of the New England Center for Neurology and Headache. These findings reinforce the potential for SB623 to provide clinically meaningful…
Content Section:
News Posts
…sandwich and diet coke), HR increased by 27bpm after 3 min standing with headache. After mild physical exertion (putting away washed clothes, up and down the stairs twice), HR increased…
Content Section:
Articles
…Newcombe enlightened us on what’s new in mTBI, highlighting the importance of pre-injury factors in symptom development, as well as describing how common post-concussion symptoms (e.g. headache, dizziness and fatigue) are…
Content Section:
Conference Reports
…I would have wished for more extensive review and discussion of treatments for neurological complications of TBI, such as post-traumatic headache, vertigo, epilepsy, cognitive and behavioural symptoms. Even though they…
Content Section:
Book Reviews
…(76.7%) and placebo (70.5%). The most common TEAEs were injection site bruising, headache, and diarrhea. Rates of treatment discontinuation due to a TEAE were low and all patients who completed…
Content Section:
News Posts
…ARIA-H (combined cerebral microhaemorrhages, cerebral macrohaemorrhages, and superficial siderosis; lecanemab (n=898): 17.3%; placebo (n=897): 9.0%), ARIA-E (edema/effusion; lecanemab (n=898): 12.6%; placebo 9n=897): 1.7%), headache (lecanemab (n=898): 11.1%; placebo (n=897): 8.1%),…
Content Section:
News Posts